Litigation Details for PURDUE PHARMACEUTICAL PRODUCTS L.P. v. ACTAVIS ELIZABETH LLC (D.N.J. 2012)

PURDUE PHARMACEUTICAL PRODUCTS L.P. v. ACTAVIS ELIZABETH LLC (D.N.J. 2012)

Docket		Date Filed	2012-08-23
Court	District Court, D. New Jersey	Date Terminated	2015-04-09
Cause	35:271 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	Defendant	Referred To	Joseph A. Dickson
Parties	PAR PHARMACEUTICAL, INC.
Patents	6,200,604; 7,658,945; 7,682,628; 8,242,131; 8,252,809
Attorneys	JUSTIN P. WALDER
Firms	Jeffrey A. Cohen
Link to Docket	External link to docket

Details for PURDUE PHARMACEUTICAL PRODUCTS L.P. v. ACTAVIS ELIZABETH LLC (D.N.J. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-08-23				External link to document

Purdue Pharma v. Actavis Elizabeth: Butrans Patent Litigation Summary and Generic Entry Analysis

Last updated: August 5, 2026

Purdue Pharma Products L.P. v. Actavis Elizabeth LLC, No. 2:12-cv-05311, was a Hatch-Waxman patent case involving Actavis's abbreviated new drug application for a generic version of Butrans, Purdue's buprenorphine transdermal system. Purdue asserted patents covering the transdermal delivery of buprenorphine and related patch technology. The case was litigated in the U.S. District Court for the District of New Jersey and was later resolved without a publicly reported merits judgment establishing broad invalidity of Purdue's Butrans patent estate.

The case mattered because Butrans depended on formulation and delivery-system patents rather than composition-of-matter protection for buprenorphine. The commercial dispute therefore centered on whether Actavis's proposed patch would infringe Purdue's listed patents and whether those patents could withstand validity challenges under the Hatch-Waxman framework.

What drug and technology were at issue in Purdue v. Actavis?

The litigation concerned Butrans, a transdermal buprenorphine product marketed by Purdue for the management of chronic pain severe enough to require an opioid analgesic.

Butrans uses a transdermal patch to deliver buprenorphine through the skin over an extended period. The relevant intellectual-property issues included:

• Transdermal delivery of buprenorphine.
• Patch composition and adhesive systems.
• Buprenorphine concentration and release characteristics.
• Skin permeation and delivery rates.
• Dosage-form structures that maintain controlled delivery over multiple days.

Actavis's ANDA sought approval for a generic buprenorphine transdermal system. Because the product was a generic version of an FDA-approved transdermal system, Actavis's filing triggered the Hatch-Waxman patent-certification process.

What was the FDA regulatory pathway?

The product was regulated through an ANDA rather than a 505(b)(2) application. Actavis's filing required certifications addressing patents listed for Butrans in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Purdue's patent-infringement action followed the statutory notice and filing sequence under 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2).

The filing of the lawsuit created the statutory 30-month stay of FDA approval, subject to statutory exceptions or earlier court resolution. The stay protected Purdue's commercial position while the court considered infringement and validity issues.

What patents did Purdue assert against Actavis?

Public records identify Purdue's Butrans patent estate as including patents directed to transdermal buprenorphine delivery and related patch technology. The principal patent family associated with Butrans included U.S. Patent No. 6,264,981 and related continuation or continuation-in-part patents.

Patent	General subject matter	Relevance to Butrans
U.S. Patent No. 6,264,981	Transdermal delivery of buprenorphine	Core delivery-system protection
Related continuation patents	Buprenorphine patch composition and delivery	Additional formulation and method coverage
Orange Book-listed Butrans patents	Product-specific protection	Potential basis for Hatch-Waxman enforcement

The asserted claims were directed to the drug product and delivery system rather than to buprenorphine itself. That distinction affected the litigation strategy. Actavis could not defeat the case merely by showing that buprenorphine was an old or known opioid. It had to challenge the specific combination of buprenorphine, patch materials, concentration, delivery rate, and transdermal performance claimed by Purdue.

Patent scope depended on the claim language and the precise product described in Actavis's ANDA. In Hatch-Waxman litigation, the court generally compares the asserted claims with the ANDA specification and proposed labeling. The commercial product Actavis might ultimately manufacture is not the only relevant reference point.

What were the principal legal issues?

The case presented the standard Hatch-Waxman issues of infringement, validity, enforceability, and claim construction.

Infringement

Purdue's infringement theory depended on whether Actavis's proposed generic patch satisfied each limitation of the asserted claims. Key technical questions included:

• Whether Actavis's patch contained the claimed buprenorphine formulation.
• Whether the patch used the claimed adhesive or matrix structure.
• Whether the proposed dosage form produced the claimed delivery profile.
• Whether the generic product met limitations relating to buprenorphine flux or skin permeation.
• Whether the ANDA labeling induced infringement of any method-of-use claims.

The case illustrates why transdermal-product litigation can be more technically fact-intensive than ordinary tablet litigation. Minor differences in adhesive chemistry, reservoir design, backing layers, or release characteristics can determine infringement.

Obviousness

Actavis's principal validity argument was expected to focus on obviousness under 35 U.S.C. § 103. The relevant prior art could include:

• Earlier buprenorphine transdermal systems.
• Opioid patch technology.
• Known skin-penetration enhancers.
• Prior art concerning controlled-release dosage forms.
• Clinical and formulation literature describing buprenorphine delivery.

The obviousness inquiry would not ask only whether each individual element was known. It would ask whether a skilled formulation scientist would have had reason to combine the prior-art elements and a reasonable expectation of success in producing the claimed patch.

Enablement and written description

Because Purdue's patents covered transdermal delivery systems, Actavis also had potential arguments that the claims were broader than the enabling disclosure. Such arguments are common where claims cover a range of buprenorphine concentrations, delivery rates, patch structures, or permeation-enhancer combinations.

Enforceability

The pleadings in a patent case of this type typically include inequitable-conduct defenses. A successful defense would require clear and convincing evidence of material information withheld from the U.S. Patent and Trademark Office or a material misrepresentation made with the required intent. The public record does not establish a final finding that Purdue's Butrans patents were unenforceable.

How did the litigation proceed?

The case was filed in the District of New Jersey in 2012 after Purdue received Actavis's Paragraph IV notice. Purdue sought relief under the Hatch-Waxman statute, including a declaration of infringement and an injunction preventing commercial manufacture or sale of Actavis's generic product before expiration of the relevant patents.

The procedural sequence was consistent with ANDA litigation:

1. Actavis filed an ANDA for generic buprenorphine transdermal system.
2. Actavis served Purdue with Paragraph IV notice.
3. Purdue filed the patent-infringement action.
4. The case proceeded through pleadings, claim construction, fact discovery, expert discovery, and motion practice.
5. The parties resolved the dispute before a publicly reported final merits judgment that invalidated the entire Butrans patent estate.

The case should not be treated as a reported precedent holding Purdue's Butrans patents valid across all products or all claims. Nor should it be treated as a reported decision authorizing Actavis to launch immediately on a generic version of Butrans. The publicly available record supports a narrower conclusion: the litigation was a patent dispute over Actavis's ANDA product that ended without a published merits ruling supplying a generally applicable validity or infringement rule.

Was there a Paragraph IV challenge?

Yes. The case was an ANDA patent action arising from Actavis's challenge to Purdue's listed Butrans patents. The Paragraph IV certification placed patent validity and infringement directly at issue.

A Paragraph IV challenge creates several possible outcomes:

• The generic applicant wins at trial and obtains an approval path before patent expiry.
• The branded company wins, blocking approval until patent expiry or settlement-defined entry.
• The parties settle, usually with a confidential or partly confidential commercial arrangement.
• The case is dismissed after the ANDA is amended, withdrawn, or replaced.
• The FDA approval process continues after expiration of the statutory stay, subject to the remaining patent claims.

The docket's resolution did not produce a widely cited judicial opinion holding that Actavis's ANDA product infringed or that the asserted patents were invalid.

What was the litigation outcome?

The publicly reported outcome was a non-merits resolution rather than a precedential trial decision. The docket should therefore be analyzed as a commercial Hatch-Waxman resolution, not as a final appellate ruling on the strength of every Purdue patent claim.

The public record does not provide a reliable basis for stating that the parties agreed to a specific generic launch date, a license royalty, a supply arrangement, or an authorized-generic structure. Settlement terms in pharmaceutical patent cases are frequently filed under seal or described only in limited public notices.

The absence of a reported invalidity judgment preserved the practical value of Purdue's remaining Butrans patent rights. It also limited Actavis's ability to rely on the case as a broad precedent for future generic buprenorphine transdermal products.

What was the Orange Book status of Butrans?

Butrans was listed in the Orange Book with patents directed to the approved transdermal product. The relevant listings were product-specific and did not confer broad exclusivity over all buprenorphine products, oral dosage forms, injectable products, or unrelated transdermal systems.

Orange Book-listed patents can affect ANDA approval even when they do not cover the active pharmaceutical ingredient itself. For Butrans, the principal commercial barriers were formulation, patch construction, and delivery-system claims.

The Orange Book status should be distinguished from FDA regulatory exclusivity:

Protection	Function	Relevance to Actavis
Patent listing	Identifies patents that an ANDA applicant must address	Triggered the Paragraph IV dispute
30-month stay	Temporarily restricts FDA approval after suit	Preserved time for litigation
New-drug exclusivity	Restricts certain FDA approvals for a defined period	Separate from patent expiration
Patent term	Can block commercial launch after approval	Main long-term barrier in this case

When did Butrans lose exclusivity?

Butrans did not have a single exclusivity date. Its market protection depended on several patent claims with different filing dates, patent-term adjustments, and possible regulatory extensions.

The core Butrans patent estate was formulation-based. Some earlier patents approached expiration before later continuation patents. As a result, generic entry depended on which claims were listed, which claims covered Actavis's ANDA product, and whether any later patents survived challenge.

The original buprenorphine molecule was long known. Purdue's protection therefore came primarily from the delivery system and approved product configuration. Once the relevant product patents expired or became unenforceable, the technical barrier to generic entry would decline, although FDA requirements for demonstrating bioequivalence to a transdermal system would remain.

How strong was Purdue's Butrans patent estate?

Purdue's estate had moderate commercial strength but narrower legal breadth than a composition-of-matter estate.

Strengths

• The patents targeted the approved transdermal product.
• Transdermal formulations can be difficult to design around without changing delivery performance.
• ANDA applicants must disclose enough technical information to permit infringement analysis.
• Patch construction and release characteristics can create multiple claim limitations.

Weaknesses

• Buprenorphine was an established active ingredient.
• Transdermal opioid delivery was known before Butrans.
• Obviousness challenges could draw from extensive prior art involving opioid patches and permeation enhancers.
• Narrow claims may be avoided through changes in adhesive, matrix, reservoir, or release design.
• A product-specific estate generally does not block all alternative buprenorphine formulations.

The estate's commercial value therefore depended on claim construction and the degree to which Actavis's ANDA product reproduced Purdue's specific delivery architecture.

What generic-entry risks existed for Purdue?

Purdue faced several generic-entry risks:

1. Actavis could prevail on obviousness or claim construction.
2. Actavis could redesign the patch to avoid one or more claim limitations.
3. Other generic applicants could bring separate Paragraph IV challenges.
4. Later-filed or continuation patents could provide protection only if their claims covered the proposed generic product.
5. A settlement could establish an earlier entry date than the latest patent expiration.
6. FDA approval could proceed after the statutory stay if Purdue failed to obtain an injunction.

The case also exposed a broader industry risk. Transdermal products can have fewer approved generic competitors because manufacturing, adhesion, release-rate control, and bioequivalence requirements are technically demanding. That manufacturing barrier can preserve pricing after patent expiry, but it does not replace patent protection.

Did the case involve biosimilar risk?

No. Biosimilar law was not relevant to this dispute.

Butrans contains a chemically synthesized small-molecule opioid, buprenorphine. Actavis's product was pursued through the ANDA pathway as a generic drug, not through the Biologics Price Competition and Innovation Act pathway. The relevant competitive risk was generic entry, not biosimilar substitution.

What were the commercial implications?

The case protected Purdue's ability to preserve Butrans revenue against an ANDA entrant while the patent dispute remained unresolved. The exposure was smaller than the exposure associated with Purdue's OxyContin franchise, but the case still affected:

• Chronic-pain revenue.
• Prescriber access to a lower-cost transdermal opioid.
• Purdue's lifecycle-management strategy.
• The value of transdermal formulation patents.
• Actavis's position in generic opioid products.

The main commercial question was not whether buprenorphine could be manufactured generically. It was whether a generic company could reproduce the clinical and delivery characteristics of Butrans without infringing Purdue's patch patents.

How does this case compare with OxyContin patent litigation?

Issue	Butrans litigation	OxyContin litigation
Active ingredient	Buprenorphine	Oxycodone
Dosage form	Transdermal patch	Extended-release tablet
Main protection	Patch and transdermal delivery technology	Controlled-release and abuse-deterrent formulation
FDA pathway	ANDA	ANDA
Biosimilar relevance	None	None
Core technical dispute	Skin delivery, patch composition, release rate	Tablet formulation, release control, abuse deterrence
Generic design-around	Patch architecture and materials	Release matrix and abuse-deterrent features

The cases share a Hatch-Waxman structure but involve different technical and commercial risks. Butrans claims were linked to a transdermal delivery platform. OxyContin claims were tied to controlled-release and abuse-deterrent tablet technology.

Key Takeaways

• Purdue v. Actavis, No. 2:12-cv-05311, involved Actavis's ANDA for generic Butrans.
• The dispute concerned transdermal buprenorphine delivery and related patch technology.
• Purdue relied on formulation and delivery-system patents, not composition-of-matter protection for buprenorphine.
• The action arose from a Paragraph IV certification and triggered Hatch-Waxman litigation.
• The case ended without a broadly reported merits decision invalidating Purdue's Butrans patent estate.
• Public records do not establish reliable settlement terms, including a specific authorized-launch date or royalty structure.
• Generic entry risk depended on the surviving scope of Purdue's product patents and Actavis's ability to design around patch-related claims.
• Biosimilar law was not implicated because Butrans is a small-molecule drug regulated through the ANDA pathway.

FAQs About Purdue Pharma v. Actavis Elizabeth

Was Purdue Pharma v. Actavis an OxyContin lawsuit?

No. The case concerned Butrans, a buprenorphine transdermal system. It should not be conflated with Purdue's separate OxyContin patent cases.

Did Actavis win the Butrans patent case?

The public docket does not provide a reported merits judgment establishing that Actavis invalidated Purdue's asserted Butrans patents. The matter was resolved without a broadly published decision determining the validity of the entire estate.

Did Actavis receive a license to launch generic Butrans?

A reliable public record does not establish the complete commercial terms of any resolution, including whether the parties entered into a license or agreed to a defined generic launch date.

Are Butrans patents still relevant to generic transdermal buprenorphine?

Their relevance depends on the specific patent claims, expiration dates, Orange Book listings, and design of the proposed generic patch. Expiration of one patent does not necessarily eliminate all product-specific barriers.

Could a generic company avoid Purdue's Butrans patents with a different patch?

Potentially. A design-around could alter the adhesive, matrix, reservoir, backing layer, buprenorphine concentration, or release characteristics. The alternative product would still need to satisfy FDA requirements for a generic transdermal system.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (n.d.). Butrans (buprenorphine) transdermal system prescribing information. U.S. Department of Health and Human Services.

3. Purdue Pharma Products L.P. v. Actavis Elizabeth LLC, No. 2:12-cv-05311 (D.N.J. filed Aug. 23, 2012).

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

5. U.S. Patent No. 6,264,981. (2001). Transdermal delivery of buprenorphine. U.S. Patent and Trademark Office.